Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors

Area of Science:

• Immunology
• Gene Therapy
• Viral Vectors

Background:

• Clinical use of adeno-associated viral (AAV) vectors is growing, highlighting the need to understand immune responses.
• AAV vector immunogenicity can limit gene therapy efficacy, causing neutralization, inflammation, and toxicity.
• Current preclinical models often fail to predict clinical immune responses to AAV therapies.

Purpose of the Study:

• To review current knowledge on immune responses to AAV vectors.
• To explore mechanisms of innate, humoral, and adaptive immunity triggered by AAV.
• To discuss strategies for mitigating immune responses for safer gene therapies.

Main Methods:

• Literature review of studies on AAV vector immunogenicity.
• Analysis of innate immune pathways activated by AAV.
• Examination of humoral and adaptive immune responses, including antibody production and T-cell activation.
• Review of methods to control or reduce immune responses.

Main Results:

• AAV vectors elicit complex immune responses involving innate and adaptive immunity.
• Pre-existing antibodies and de novo immune responses can impact efficacy and safety.
• Mechanisms of immune tolerance and modulation are being investigated.
• Strategies to manage immunogenicity include vector engineering and immunomodulatory treatments.

Conclusions:

• Addressing AAV vector immunogenicity is essential for successful gene therapy.
• Further research is needed to bridge the gap between preclinical findings and clinical outcomes.
• Mitigating immune responses will lead to more effective and durable gene therapies.